Breast Cancer Treatment Based on Organ-like Culture

Study Overview
=================
Brief Summary
-----------------
Based on the breast cancer organ platform, this experiment establishes a drug sensitivity test method that is closer to the body tumor in breast cancer, provides a basis for the accurate treatment of breast cancer, and discusses the possible mechanism of breast cancer drug resistance.

Official Title
-----------------
Sensitivity Detection and Drug Resistance Mechanism of Breast Cancer Therapeutic Drugs Based on Organ-like Culture

Conditions
-----------------
Breast Cancer Organoids

Intervention / Treatment
-----------------
* Drug: Trastuzumab
* Drug: Doxorubicin Hydrochloride
* Drug: Epirubicin hydrochloride
* Drug: Fluorouracil
* Drug: Paclitaxel
* Drug: Gemcitabine
* Drug: Cisplatin
* Drug: Recombinant Human Endostatin
* Drug: Pirarubicin hydrochloride
* Drug: Pyrrolidine
* Drug: Ixabepilone
* Drug: Tamoxifen citrate
* Drug: Vinorelbine tartrate
* Drug: Carboplatin
* Drug: Methotrexate
* Drug: Eribulin mesylate
* Drug: Toremifene citrate
* Drug: Anastrozole
* Drug: Letrozole
* Drug: Exemestane
* Drug: Fulvestrant
* Drug: Olaparib
* Drug: Bevacizumab
* Drug: Apatinib mesylate
* Drug: Pattozumab
* Drug: Capecitabine
* Drug: Ear particles
* Drug: Aidi Injection
* Drug: Cyclophosphamide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with breast cancer and the largest tumor diameter ≥ 3cm No previous chemotherapy regimen age 18-65 years old Can obtain the tumor tissue specimens required for culture Heart, liver, kidney and bone marrow hematopoietic function is good Know and sign the informed consent form Exclusion Criteria: Pregnant or lactating women Also suffering from other cancer patients There are serious uncontrolled medical diseases or acute infections Those who are known to be allergic to this study drug or a variety of previous drugs The patient cannot understand the purpose of the study or disagree with the requirements of the study. Other investigators believe that patients who are not suitable for this study group

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HER2+ Breast Cancer<br> | Drug: Trastuzumab<br>* Trastuzumab Injection<br>Drug: Doxorubicin Hydrochloride<br>* Doxorubicin Hydrochloride Injection<br>Drug: Epirubicin hydrochloride<br>* Epirubicin hydrochloride injection<br>Drug: Fluorouracil<br>* Fluorouracil injection<br>Drug: Paclitaxel<br>* Paclitaxel injection<br>Drug: Gemcitabine<br>* Gemcitabine injection<br>Drug: Cisplatin<br>* Cisplatin injection<br>Drug: Recombinant Human Endostatin<br>* Recombinant Human Endostatin Injection<br>Drug: Pirarubicin hydrochloride<br>* Pirarubicin hydrochloride injection<br>Drug: Pyrrolidine<br>* Pyrrolidine tablets<br>Drug: Ixabepilone<br>* Ixapilone Injection<br>Drug: Tamoxifen citrate<br>* Tamoxifen citrate tablets<br>Drug: Vinorelbine tartrate<br>* Vinorelbine tartrate injection<br>Drug: Carboplatin<br>* Carboplatin injection<br>Drug: Methotrexate<br>* Methotrexate injection<br>Drug: Eribulin mesylate<br>* Eribulin mesylate injection<br>Drug: Toremifene citrate<br>* Toremifene citrate tablets<br>Drug: Anastrozole<br>* Anastrozole tablets<br>Drug: Letrozole<br>* Letrozole tablets<br>Drug: Exemestane<br>* Exemestane tablets<br>Drug: Fulvestrant<br>* Fulvestrant injection<br>Drug: Olaparib<br>* Olapani pill<br>Drug: Bevacizumab<br>* Bevacizumab injection<br>Drug: Apatinib mesylate<br>* Apatinib mesylate tablets<br>Drug: Pattozumab<br>* Pattozumab injection<br>Drug: Capecitabine<br>* Capecitabine tablets<br>Drug: Ear particles<br>* Ear particles<br>Drug: Aidi Injection<br>* Aidi Injection<br>Drug: Cyclophosphamide<br>* Cyclophosphamide injection<br>|
| ER+ Breast Cancer<br> | Drug: Trastuzumab<br>* Trastuzumab Injection<br>Drug: Doxorubicin Hydrochloride<br>* Doxorubicin Hydrochloride Injection<br>Drug: Epirubicin hydrochloride<br>* Epirubicin hydrochloride injection<br>Drug: Fluorouracil<br>* Fluorouracil injection<br>Drug: Paclitaxel<br>* Paclitaxel injection<br>Drug: Gemcitabine<br>* Gemcitabine injection<br>Drug: Cisplatin<br>* Cisplatin injection<br>Drug: Recombinant Human Endostatin<br>* Recombinant Human Endostatin Injection<br>Drug: Pirarubicin hydrochloride<br>* Pirarubicin hydrochloride injection<br>Drug: Pyrrolidine<br>* Pyrrolidine tablets<br>Drug: Ixabepilone<br>* Ixapilone Injection<br>Drug: Tamoxifen citrate<br>* Tamoxifen citrate tablets<br>Drug: Vinorelbine tartrate<br>* Vinorelbine tartrate injection<br>Drug: Carboplatin<br>* Carboplatin injection<br>Drug: Methotrexate<br>* Methotrexate injection<br>Drug: Eribulin mesylate<br>* Eribulin mesylate injection<br>Drug: Toremifene citrate<br>* Toremifene citrate tablets<br>Drug: Anastrozole<br>* Anastrozole tablets<br>Drug: Letrozole<br>* Letrozole tablets<br>Drug: Exemestane<br>* Exemestane tablets<br>Drug: Fulvestrant<br>* Fulvestrant injection<br>Drug: Olaparib<br>* Olapani pill<br>Drug: Bevacizumab<br>* Bevacizumab injection<br>Drug: Apatinib mesylate<br>* Apatinib mesylate tablets<br>Drug: Pattozumab<br>* Pattozumab injection<br>Drug: Capecitabine<br>* Capecitabine tablets<br>Drug: Ear particles<br>* Ear particles<br>Drug: Aidi Injection<br>* Aidi Injection<br>Drug: Cyclophosphamide<br>* Cyclophosphamide injection<br>|
| Triple Negative Breast Cancer<br> | Drug: Trastuzumab<br>* Trastuzumab Injection<br>Drug: Doxorubicin Hydrochloride<br>* Doxorubicin Hydrochloride Injection<br>Drug: Epirubicin hydrochloride<br>* Epirubicin hydrochloride injection<br>Drug: Fluorouracil<br>* Fluorouracil injection<br>Drug: Paclitaxel<br>* Paclitaxel injection<br>Drug: Gemcitabine<br>* Gemcitabine injection<br>Drug: Cisplatin<br>* Cisplatin injection<br>Drug: Recombinant Human Endostatin<br>* Recombinant Human Endostatin Injection<br>Drug: Pirarubicin hydrochloride<br>* Pirarubicin hydrochloride injection<br>Drug: Pyrrolidine<br>* Pyrrolidine tablets<br>Drug: Ixabepilone<br>* Ixapilone Injection<br>Drug: Tamoxifen citrate<br>* Tamoxifen citrate tablets<br>Drug: Vinorelbine tartrate<br>* Vinorelbine tartrate injection<br>Drug: Carboplatin<br>* Carboplatin injection<br>Drug: Methotrexate<br>* Methotrexate injection<br>Drug: Eribulin mesylate<br>* Eribulin mesylate injection<br>Drug: Toremifene citrate<br>* Toremifene citrate tablets<br>Drug: Anastrozole<br>* Anastrozole tablets<br>Drug: Letrozole<br>* Letrozole tablets<br>Drug: Exemestane<br>* Exemestane tablets<br>Drug: Fulvestrant<br>* Fulvestrant injection<br>Drug: Olaparib<br>* Olapani pill<br>Drug: Bevacizumab<br>* Bevacizumab injection<br>Drug: Apatinib mesylate<br>* Apatinib mesylate tablets<br>Drug: Pattozumab<br>* Pattozumab injection<br>Drug: Capecitabine<br>* Capecitabine tablets<br>Drug: Ear particles<br>* Ear particles<br>Drug: Aidi Injection<br>* Aidi Injection<br>Drug: Cyclophosphamide<br>* Cyclophosphamide injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection of cell viability | 1. The organ-like organ was assayed for cell viability using CellTiter Glo 3D reagent, and the curve was used to obtain a half-inhibitory concentration range. The dose was adjusted according to the half-inhibition concentration range to obtain an accurate half-inhibitory concentration. | 8 weeks before neoadjuvant chemotherapy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection of in vitro model drug sensitivity | 2. In vitro model drug sensitivity: sensitive and insensitive | 8 weeks before neoadjuvant chemotherapy | 
| Clinical efficacy assessment according to RECIST criteria | Clinical efficacy evaluation according to RECIST criteria: imaging ultrasonography, histological pathology. | 8 weeks before neoadjuvant chemotherapy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Drug sensitivity experiment, Resistance mechanism research